Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy 2019 | Predicting MM response to cellular and immunotherapies

Paola Neri • 17 May 2019
COMy 2019
Multiple Myeloma Antibodies CAR-T Checkpoint inhibitors Daratumumab

Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discusses how immune deregulation can be used to predict response to cellular therapies and immunotherapies, such as CAR T-cell products and monocloncal antibodies. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Paola Neri

Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level
7:13
Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level
Paola Neri • 23 Oct 2025
Understanding mechanisms of resistance to targeted therapies in myeloma
Understanding mechanisms of resistance to targeted therapies in myeloma
Paola Neri • 3 May 2024
Using the available repertoire of bispecific antibodies for treating multiple myeloma
1:45
Using the available repertoire of bispecific antibodies for treating multiple myeloma
Paola Neri • 17 Feb 2024
Antigen loss as a key driver of resistance to anti-BCMA T-cell therapies in myeloma
1:20
Antigen loss as a key driver of resistance to anti-BCMA T-cell therapies in myeloma
Paola Neri • 17 Feb 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Paola Neri • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Paola Neri • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Paola Neri • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Paola Neri • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals